688606 Hangzhou Alltest Biotech
WatchlistHangzhou Alltest Biotech News
Aotai Biotech (688606.SH): Repurchased 400,000 shares at a total cost of 22.64 million yuan
Gelonghui (688606.SH) announced on November 1 | Aotai Biotech () announced that as of October 31, 2023, the company has repurchased a total of 400,000 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase transaction price is 58.01 yuan/share, the lowest price is 55.11 yuan/share, and the total capital paid is RMB 22,641,640.33.
Aotai Biotech (688606.SH): A total of 400,000 shares have been repurchased by the end of September
Glonghui, October 10, 丨 Aotai Biotech (688606.SH) announced that as of September 30, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22,641,640.33 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): At a cost of 22.641,600 yuan, a total of 400,000 shares have been repurchased
Glonghui September 27丨Aotai Biotech (688606.SH) announced that as of the close of trading on September 27, 2023, the company had repurchased 400,000 shares of the company through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.5045% of the company's total share capital of 79,280,855 shares. The highest repurchase price was 58.01 yuan/share, the lowest price was 55.11 yuan/share, and the total amount of capital paid was RMB 22.641,600 (excluding transaction fees such as stamp duty and transaction fees).
Aotai Biotech (688606.SH): The company has not implemented a share repurchase
Glonghui September 4 丨 Aotai Biotech (688606.SH) announced that as of August 31, 2023, the company has not implemented a share repurchase.
Aotai Biotech (688606.SH) released semi-annual results, net profit of 71.18 million yuan, a year-on-year decrease of 94.54%
Aotai Biotech (688606.SH) disclosed the 2023 semi-annual report. The company achieved revenue of 3.88 during the reporting period...
The controlling shareholder of Aotai Biotech (688606.SH) proposed to spend 42 million yuan to 60 million yuan to buy back the shares
Aotai Biotech (688606.SH) announced that the company received actual control from the company's controlling shareholder on August 16...
Aotai Biotech (688606.SH): Fentanyl urine detection reagent obtained 510K certification from the US FDA
According to the Zhitong Finance App, Aotai Biotech (688606.SH) announced that the company has received a notice from the U.S. Food and Drug Administration (“FDA”) that the company's fentanyl urine test reagent has obtained 510K certification from the US FDA. The fentanyl urine detection reagent that obtained 510K certification from the US FDA this time is a rapid detection reagent independently developed by the company to qualitatively detect fentanyl in human urine. The detection threshold is 1 ng/ml. The product is easy to operate, no instruments required
Lu Weike, director of Aotai Biotech (688606.SH), has not reduced his holdings at the end of the holdings reduction period
According to the Zhitong Finance App, Aotai Biotech (688606.SH) announced that Lu Wei, the company's director, senior manager, and core technician, has reduced his holdings of the company by a total of 0 shares, accounting for 0% of the company's total share capital. As of the disclosure date of this announcement, the time period for the current holdings reduction plan has expired.
Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Largest Shareholder, CEO Fei Gao Sees Holdings Value Fall by 13% Following Recent Drop
Key Insights Insiders appear to have a vested interest in Hangzhou Alltest Biotech's growth, as seen by their sizeable ownership 51% of the business is held by the top 2 shareholders Using data fr
126 A-shares were registered as shares today, and Alotai Biotech paid the most dividends
Gelonghui, June 8 丨 According to statistics compiled by the equity distribution plans of listed companies, 126 A-shares were registered as shares today. Of these, 106 shares are to be distributed, 2 shares are to be increased, and 18 shares are to be distributed, transferred or transferred at the same time. In terms of dividends, the equity registration date for 106 individual stock dividends is June 8. Botuo Biotech, Jimi Technology, and Zhenhua Technology paid the most dividends, paying 22.00 yuan, 21.47 yuan, and 11.45 yuan respectively for every 10 shares. In terms of increasing share capital, the share registration date for the two individual shares transferred to increased share capital is June 8. Chenxi Airlines and Chinatungsten Hi-Tech transferred the highest number of shares, with each 10 shares being transferred separately
Alotai Biotech (688606.SH) 2022 Equity Distribution: Transferring 0.48 shares to distribute $10 per share. Stock registration on June 8
According to the Zhitong Finance App, Alotai Biotech (688606.SH) issued an announcement. The company's 2022 equity distribution will be implemented: a cash dividend of 10 yuan per share (tax included) will be distributed to all shareholders, and 0.48 shares will be transferred from the Capital Provident Fund to all shareholders. The share registration date is June 8, 2023, and the exclusion (interest) date is June 9, 2023.
Aotai Biotech's “downhill road” in the post-pandemic era
“Investor Network” Zhang Wei In the post-pandemic era, how many companies that once relied on the COVID-19 pandemic to improve their performance still have? The answer can be seen from the newly disclosed quarterly reports. On April 29, the in vitro diagnostic reagent manufacturer Hangzhou Aotai Biotechnology Co., Ltd. (hereinafter referred to as “Aotai Biotech”, 688606.SH) released a quarterly report showing that the company's revenue for the first quarter of this year (Q1) fell 88.75% year on year, and net profit fell 96.14% year on year, in stark contrast to 2022 revenue and net profit, which increased 80.88% and 54.69% respectively. On the secondary market, on Alotai Biotech
Express News | Huahai Pharmaceutical: Received dabigatran capsule drug registration certificate
Alotai Biotech (688606.SH) announced 2022 results, net profit of 1,184 million yuan, a year-on-year increase of 54.69%, plans to distribute 100 yuan for every 10 shares to increase 4.8 shares
According to the Zhitong Finance App, Alotai Biotech (688606.SH) released its 2022 annual report, with operating income of 3.389 billion yuan, an increase of 80.88% over the previous year; net profit attributable to shareholders of listed companies was 1,184 million yuan, an increase of 54.69% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1.16 billion yuan, an increase of 59.14% over the previous year; basic earnings per share of 21.97 yuan; plans to distribute a cash dividend of 100 yuan (tax included) for every 10 shares and the proposed capital reserve to transfer 4.8 shares to all shareholders for every 10 shares.
Alotai Biotech (688606.SH) released first-quarter results, with net profit of 405.325 million yuan, a year-on-year decrease of 96.14%
According to the Zhitong Finance App, Alotai Biotech (688606.SH) released a report for the first quarter of 2023, with operating income of 236 million yuan, down 88.75% from the previous year; net profit attributable to shareholders of listed companies was 405.325 million yuan, down 96.14% from the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 288.76 million yuan, down 97.24% from the previous year; basic earnings per share were 0.75 yuan.
Why You Should Care About Hangzhou Alltest Biotech's (SHSE:688606) Strong Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earn
Alotai Biotech (688606.SH): More than half of the holdings reduction period, director and core technician Lu Weike has not reduced his holdings
Glonghui, April 3, 丨 Alotai Biotech (688606.SH) announced that on April 3, 2023, the company received a “Notice on the progress of Alotai Biotech's holdings reduction” issued by director, senior management and core technician Lu Weike. As of the announcement date, Luvik had reduced its stock holdings by a total of 0 shares, accounting for 0% of the company's total share capital. Halfway through the current holdings reduction plan, the holdings reduction plan has not yet been implemented.
448,900 restricted shares of Alotai Biotech (688606.SH) will be listed for circulation from March 27
According to the Zhitong Finance App, Alotai Biotech (688606.SH) issued an announcement that the restricted shares listed and distributed this time are restricted shares strategically placed for the company's first public offering. The sales limit period is 24 months from the date the company's shares are listed. The number of shares whose sale restrictions were lifted and applied for listing and circulation this time was 448,900 shares. The total number of shareholders involved in restricted shares was 1, accounting for 0.83% of the company's total share capital. This portion of restricted shares will be listed for circulation on March 27, 2023.
Alotai Biotech (688606.SH) performance report: 2022 net profit increased 69.73% to 1,299.6 billion yuan
Glonghui, Feb. 27丨Alotai Biotech (688606.SH) announced its 2022 annual performance report. In 2022, the company achieved total revenue of 3.452 billion yuan, an increase of 84.25% over the same period last year; total profit of 1,511 billion yuan, an increase of 68.73% over the same period of the previous year; realized net profit attributable to parent company owners after deducting non-recurring profit and loss of 1,275 million yuan, an increase of 74.88% over the same period last year; basic earnings per share 24.11 yuan.
Alotai Biotech (688606.SH) is forecasting a net profit of 1,375 million yuan to 1.41 billion yuan in 2022, an increase of 79.58% to 84.15% over the previous year
According to the Zhitong Finance App, Alotai Biotech (688606.SH) announced that the company expects to achieve net profit of 1,375 million yuan to 1.41 billion yuan in 2022. Compared with the same period of the previous year (statutory disclosure data), it will increase by 60,931111 million yuan to 644.311 million yuan, an increase of 79.58% to 84.15% over the previous year. This is due to the increase in sales of the company's non-COVID-19 testing products and COVID-19 testing products during the reporting period. Among them: In terms of non-COVID-19 testing products, it mainly benefits from the spread of infectious disease testing products, drugs and drugs in the company's main business